- Home
- ALNY vs CTVA Comparison
ALNY vs CTVA Comparison
Compare ALNY & CTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- CTVA
- Stock Information
- Founded
- ALNY 2002
- CTVA 2018
- Country
- ALNY United States
- CTVA United States
- Employees
- ALNY N/A
- CTVA N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- CTVA Farming/Seeds/Milling
- Sector
- ALNY Health Care
- CTVA Consumer Staples
- Exchange
- ALNY Nasdaq
- CTVA Nasdaq
- Market Cap
- ALNY 42.9B
- CTVA 48.7B
- IPO Year
- ALNY 2004
- CTVA N/A
- Fundamental
- Price
- ALNY $458.28
- CTVA $72.39
- Analyst Decision
- ALNY Strong Buy
- CTVA Strong Buy
- Analyst Count
- ALNY 27
- CTVA 14
- Target Price
- ALNY $401.92
- CTVA $80.43
- AVG Volume (30 Days)
- ALNY 1.3M
- CTVA 4.0M
- Earning Date
- ALNY 07-31-2025
- CTVA 08-06-2025
- Dividend Yield
- ALNY N/A
- CTVA 1.00%
- EPS Growth
- ALNY N/A
- CTVA 60.76
- EPS
- ALNY N/A
- CTVA 2.03
- Revenue
- ALNY $2,461,963,000.00
- CTVA $17,177,000,000.00
- Revenue This Year
- ALNY $33.75
- CTVA $4.47
- Revenue Next Year
- ALNY $31.66
- CTVA $3.54
- P/E Ratio
- ALNY N/A
- CTVA $35.52
- Revenue Growth
- ALNY 5.01
- CTVA 1.63
- 52 Week Low
- ALNY $205.87
- CTVA $53.40
- 52 Week High
- ALNY $462.88
- CTVA $77.41
- Technical
- Relative Strength Index (RSI)
- ALNY 85.86
- CTVA 50.49
- Support Level
- ALNY $421.81
- CTVA $70.82
- Resistance Level
- ALNY $445.20
- CTVA $72.65
- Average True Range (ATR)
- ALNY 17.25
- CTVA 1.21
- MACD
- ALNY 3.15
- CTVA 0.08
- Stochastic Oscillator
- ALNY 95.92
- CTVA 85.81
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.